Medical Technology · us
AI ECG Analysis for Heart Attack Detection Secures U.S. Procedure Code, but Insurance Reimbursement Still Faces Hurdles
Following FDA marketing authorization for Queen of Hearts, related AI ECG analysis will have a dedicated billing code in 2027. Hospitals will be able to record the service, but securing insurance payment and improving emergency care remain separate challenges.
In the emergency department, abnormalities on an electrocardiogram may influence whether a patient with myocardial infarction receives timely further intervention. Bringing artificial intelligence that helps identify these abnormalities into routine care also requires a way for the healthcare system to record its use. Powerful Medical announced on October 27 that AI-assisted ECG analysis had secured a dedicated U.S. procedure code, establishing a pathway for billing these services without yet representing a commitment by insurers to pay.
According to the company announcement and information about the same event republished by MedTech Innovator and Cardiac Vascular News, the American Medical Association (AMA) CPT Editorial Panel has established Category III procedure code 1139T, effective January 1, 2027. Its description covers noninvasive identification of ST-segment elevation myocardial infarction (STEMI), STEMI equivalents, and acute or subacute myocardial ischemia through ECG analysis using an assistive algorithm. These republications help cross-check the announcement's contents; they are not independent clinical validations.
Queen of Hearts, which performs this analysis, received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) in September 2026, according to company materials. Intended for patients with suspected acute coronary syndrome, it helps healthcare professionals identify situations that may require urgent cardiology evaluation or even earlier cardiac catheterization. One use emphasized by the company is identifying ECG clues that may indicate acute coronary artery occlusion despite the absence of typical ST-segment elevation.
This also clarifies the tool's clinical role: AI assists with identification and alerts, while subsequent management remains a matter of judgment for the medical team. Myocardial infarction and myocardial ischemia, both listed in the code, are also not identical diagnoses. Algorithmic alerts cannot all be interpreted as confirmed myocardial infarction.
Regarding the evidence, Powerful Medical says the technology is supported by more than 20 peer-reviewed studies, including randomized controlled trials, covering more than 40,000 patients across four continents. However, this announcement did not detail each study's dataset, study population, model version, or diagnostic performance, nor did it provide sufficient detail to compare outcomes from use at different hospitals. The total volume of research therefore cannot be directly translated into accuracy in every emergency department setting or the extent of improvement in patient survival.
The next steps within the healthcare system also need to be considered separately. Code 1139T will be billed alongside standard 12-lead ECG codes 93000, 93005, and 93010, allowing the AI analysis service to be recorded separately. Category III codes are used for emerging medical technologies and services and can help accumulate utilization data. FDA marketing authorization, procedure coding, and insurance reimbursement each address different questions. The new code itself neither establishes insurance coverage nor sets a payment amount.
For hospitals, this development provides an additional administrative basis for adopting AI ECG analysis. More substantive evidence will come from whether it can shorten the wait for appropriate intervention in routine workflows while controlling false positives and missed detections, and whether payers are willing to pay for that clinical value. This announcement has not yet provided reimbursement agreements or payment standards. There is still some distance between being billable and achieving sustained use.